Skip to content
OpenCapital
Get started

Opko Health OPK Pharmaceutical — Research And Development Expense

Other segment segments

Diagnostics
$312K-42.0%

Similar metrics at other companies

Baxter International logo
BAXPharmaceuticals — Research and development expenses
$22M-15.4%
Vertex Pharmaceuticals logo
VRTXPharmaceuticals — Research expenses
$205M-0.5%
Abbott logo
ABTEstablished Pharmaceuticals — R&D
$41M-2.4%
Johnson & Johnson logo
JNJInnovative Medicine — Research and development expense
$2.81B+10.4%
Bausch + Lomb logo
BLCOPharmaceuticals — R&D
$22M+144%
AnaptysBio, Inc. logo
ANABBiopharma Company — Research And Development Expense Excluding Acquired In Process Cost
$34.9M-8.4%

Other financials

Income statement

See full
Revenue$124.2M-17.2%
Gross profit$45.8M+7.4%
Operating income-$51.0M+24.0%
Net income-$54.8M+18.9%
EPS (diluted)-$0.07+30.0%

Balance sheet

See full
Cash & equivalents$40.6M-62.5%
Total debt$52.8M-4.2%
Total equity$1.2B-8.2%
Total assets$1.9B-12.8%

Cash flow

See full
Operating cash flow-$19.3M+44.1%
CapEx$1.8M-42.6%
Free cash flow-$21.1M+44.0%

Valuation

See full
Market cap$1.13B+10.0%
P/S1.9×+0.5×

Profitability

See full
Gross margin36%+4.2pp
Operating margin-17.4%-5.6pp
Net margin-36.6%-44.8pp
FCF margin-30%+0.1pp

Returns & leverage

See full
Return on equity-16.9%-21.7pp
Debt / equity0×0.0×
Current ratio3.6×+1.1×

Where this comes from

Reported directly by Opko Health in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Opko Health’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opko Health's pharmaceutical — research and development expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opko Health's pharmaceutical — research and development expense?
Opko Health (OPK) reported pharmaceutical — research and development expense of $28.75M in Q1 2026.
How has Opko Health's pharmaceutical — research and development expense changed year-over-year?
Opko Health's pharmaceutical — research and development expense decreased by 4.9% year-over-year, from $30.24M to $28.75M.
What is the long-term trend for Opko Health's pharmaceutical — research and development expense?
Over 2 years (2023 to 2025), Opko Health's pharmaceutical — research and development expense has grown at a 18.4% compound annual growth rate (CAGR), from $87.01M to $121.91M.
What does pharmaceutical — research and development expense mean?
The costs incurred by the pharmaceutical segment to discover, develop, and test new drug candidates or improve existing pharmaceutical products. This reflects the company's investment in future growth and long-term pipeline innovation.